Full text is available at the source.
Abstract
Liraglutide, a lipidated glucagon-like peptide-1 receptor agonist, presents unique regulatory challenges in demonstrating structural comparability.
- Synthetic peptides referencing recombinant-origin products may have regulatory hurdles related to their higher-order structure.
- Higher-order structural comparability assessment is crucial beyond just confirming identical primary sequences.
- Liraglutide is highlighted as a significant model due to its known self-association behavior.
Simplified